OmniStar Financial Group Inc. lifted its stake in shares of Eli Lilly And Co (NYSE:LLY) by 10.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 5,638 shares of the company’s stock after purchasing an additional 518 shares during the quarter. OmniStar Financial Group Inc.’s holdings in Eli Lilly And Co were worth $631,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Enterprise Trust & Investment Co acquired a new stake in Eli Lilly And Co in the 3rd quarter valued at about $27,000. Prestige Wealth Management Group LLC purchased a new position in shares of Eli Lilly And Co during the 2nd quarter worth about $34,000. Meridian Wealth Management LLC acquired a new stake in Eli Lilly And Co during the 1st quarter worth approximately $38,000. Manchester Financial Inc. acquired a new stake in Eli Lilly And Co during the 2nd quarter worth approximately $40,000. Finally, Litman Gregory Asset Management LLC acquired a new stake in Eli Lilly And Co during the 2nd quarter worth approximately $47,000. 76.72% of the stock is currently owned by institutional investors and hedge funds.
In related news, SVP Alfonso G. Zulueta sold 4,500 shares of the stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $117.00, for a total transaction of $526,500.00. Following the completion of the transaction, the senior vice president now directly owns 33,806 shares in the company, valued at $3,955,302. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $116.37, for a total value of $24,437,700.00. The disclosure for this sale can be found here. Insiders sold 243,452 shares of company stock valued at $28,252,925 in the last quarter. 0.11% of the stock is currently owned by corporate insiders.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.45 by $0.05. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. The company had revenue of $5.64 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the firm earned $1.48 earnings per share. The business’s revenue was up .9% on a year-over-year basis. As a group, sell-side analysts expect that Eli Lilly And Co will post 5.73 earnings per share for the current year.
Several analysts have issued reports on the stock. ValuEngine downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Bank of America set a $120.00 price objective on Eli Lilly And Co and gave the stock a “neutral” rating in a research note on Tuesday, September 10th. Nine investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Eli Lilly And Co presently has an average rating of “Hold” and a consensus price target of $122.92.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
See Also: Coverage Ratio
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.